News and Insights
Rebuild Your Company to Deliver Superior Economic and Clinical Value
The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past twenty years are now encountering major challenges. As companies grapple with the leading symptoms of these challenges — pricing pressures, pipeline productivity concerns, growing public distrust, and greater political scrutiny — it’s becoming increasingly clear that a profound shift is underway in the requirements for success in this environment.
Governments across the world are hitting the wall with respect to healthcare costs. Increasingly, manufacturers must offer a convincing case to decision makers at a country-by-country, payer-by-payer, and patient-by-patient level to pursue treatment or not, or to choose a newer, more expensive treatment vs. an older, less expensive one. That case depends on hard evidence of economic and clinical value.Read More
Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.
Whether you need a new plan or a second opinion, Numerof has the insight you're looking for.